We also demonstrated that AZD2014, a dual mTORC1 and mTORC2 inhibitor, exhibited strong cytotoxicity toward the most aggressive PHGDH-low and FKBP9-high IDH wild-type GBM-derived PDCs. This evidence concerns the gene FKBP9 and glioblastoma.